Oxford Biomedica plc
OXB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £434,525 | £212,422 | £419,622 | £1,026,855 |
| - Cash | £60,650 | £103,716 | £141,285 | £108,944 |
| + Debt | £108,761 | £111,458 | £114,281 | £9,341 |
| Enterprise Value | £482,636 | £220,164 | £392,618 | £927,252 |
| Revenue | £128,797 | £89,539 | £139,989 | £142,797 |
| % Growth | 43.8% | -36% | -2% | – |
| Gross Profit | £53,021 | £39,727 | £69,181 | £82,640 |
| % Margin | 41.2% | 44.4% | 49.4% | 57.9% |
| EBITDA | -£14,333 | -£148,618 | -£10,797 | £33,224 |
| % Margin | -11.1% | -166% | -7.7% | 23.3% |
| Net Income | -£43,190 | -£157,490 | -£39,157 | £19,011 |
| % Margin | -33.5% | -175.9% | -28% | 13.3% |
| EPS Diluted | -0.42 | -1.63 | -0.41 | 0.22 |
| % Growth | 74.2% | -297.6% | -286.4% | – |
| Operating Cash Flow | -£50,628 | -£28,517 | -£12,615 | £25,455 |
| Capital Expenditures | -£7,496 | -£9,832 | -£16,296 | -£9,461 |
| Free Cash Flow | -£58,124 | -£38,349 | -£28,911 | £15,994 |